The star of Monday’s deal is gusacitinib, a small-molecule drug that Formation is developing for chronic hand eczema. Sanofi will explore additional indications for gusacitinib in a Phase I study.

Having secured one of last year’s largest funding rounds, AI-focused Formation Bio is now eyeing up 545 million euros ($626 ...

Stryker has been in a holding pattern, posting a small return of 1.1% while floating around $376.76. Is now the time to buy ...

Buying $1000 In SYK: If an investor had bought $1000 of SYK stock 10 years ago, it would be worth $3,978.93 today based on a ...

In this article, we are going to take a look at where Stryker Corporation (NYSE:SYK) stands against other best medical device stocks to buy now. On April 16, CNBC reported that Trump’s tariffs ...

Investors in Stryker Corp (Symbol: SYK) saw new options become available today, for the August 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SYK ...

(Photo credit should read XU CONGJUN / Feature China/Future Publishing via Getty Images) We believe Intuitive Surgical stock (NASDAQ NDAQ: ISRG) is a better pick than Stryker stock (NYSE ...

Investors in Stryker Corp (Symbol: SYK) saw new options begin trading today, for the September 2026 expiration. One of the key data points that goes into the price an option buyer is willing to ...

Spleen tyrosine kinase (SYK) is a non-receptor tyrosine kinase that has long been thought to exclusively mediate signalling by receptors of the adaptive immune response (B cell receptors (BCRs ...